# SOPHiA GENETICS SA (SOPH) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $8.09, market value $689 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). SOPHiA GENETICS SA reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 8.0×**. Each dollar of revenue is priced at 8.0×.
- **Price / book: 8.3×**. The shares trade at 8.3× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -7.3%** (5-yr avg -23.1%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Gross margin: 66.6%**. SOPHiA GENETICS SA keeps 66.6% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: -85.5%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -102.2%**. The company reported a net loss over the last twelve months.
- **Return on equity: -167.6%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -299.8%**. Return on all capital, debt included, is -299.8%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -49.6%**. Each dollar of assets produces -49.6% of profit.

## Growth
- **Revenue growth (1 yr): 18.6%** (3-yr 17.6%/yr, 5-yr 22.2%/yr). Revenue grew 18.6% over the last year, against 22.2% a year compounded over five years.
- **EPS growth (1 yr): -23.2%**. Earnings per share fell 23.2%, slower than revenue, so margins compressed.

## Financial health
- **Debt to equity: 1.01**. Debt is 1.01 times equity, a leveraged balance sheet that needs steady cash flow to service.
- **Net debt / EBITDA: 0.4×**. It would take 0.4 years of operating earnings to repay net borrowings, within the comfortable range.
- **Interest coverage: -11.1×**. Operating profit covers interest only -11.1×: fragile.
- **Altman Z-score: 3.01**. A Z-score of 3.01 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. SOPHiA GENETICS SA does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 137.2%** (YTD 73.2%, 3-mo 61.8%). The shares are up 137.2% over twelve months including dividends.
- **From 52-week high: -9.9%** (161.0% above the low). Trading 10% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 56**. An RSI of 56 is neutral.
- **Beta (1 yr): 1.42** (volatility 70%). Beta of 1.42 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=SOPH · Page: https://foliofundamentals.com/stocks/soph

Not investment advice.